Flu Shot and COVID-19 Vaccine Found Compatible

Maryland, US-based Novavax, Inc. announced on June 14, 2021, data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax COVID-19] and an approved from Seqirus, either adjuvanted, trivalent seasonal influenza vaccine, or a cell-based, quadrivalent seasonal influenza vaccine.

The non-peer-reviewed findings suggest simultaneous vaccination may be a viable immunization strategy.

In addition, the protection afforded by the Novavax COVID-19 candidate vaccine was consistent with the main study at 87.5% and 89.8%, respectively.

A preprint of the manuscript, 'Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines,' is available at medRxiv.org.